ValuEngine Upgrades DexCom (NASDAQ:DXCM) to Strong-Buy

ValuEngine upgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a strong-buy rating in a research report report published on Friday, ValuEngine reports.

Other analysts have also recently issued reports about the stock. BidaskClub cut shares of DexCom from a buy rating to a hold rating in a research note on Tuesday, March 26th. Northland Securities reissued a hold rating and set a $125.00 price objective on shares of DexCom in a research note on Thursday, June 6th. Zacks Investment Research raised shares of DexCom from a hold rating to a buy rating and set a $138.00 price objective for the company in a research note on Monday, May 6th. BMO Capital Markets boosted their price objective on shares of DexCom from $167.00 to $172.00 and gave the company an outperform rating in a research note on Thursday, May 2nd. Finally, Raymond James lowered their price objective on shares of DexCom from $160.00 to $150.00 and set an outperform rating for the company in a research note on Thursday, May 2nd. Four analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $150.65.

DXCM stock opened at $150.80 on Friday. The company has a market capitalization of $13.73 billion, a price-to-earnings ratio of 502.67 and a beta of 0.70. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75. DexCom has a one year low of $90.61 and a one year high of $157.50.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.12. The firm had revenue of $280.50 million during the quarter, compared to analysts’ expectations of $246.10 million. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. DexCom’s revenue for the quarter was up 52.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) EPS. As a group, sell-side analysts expect that DexCom will post 0.81 EPS for the current year.

In related news, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $115.05, for a total transaction of $46,020.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew K. Balo sold 7,825 shares of the company’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $125.00, for a total transaction of $978,125.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,929 shares of company stock valued at $7,771,666. 1.80% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Laurel Wealth Advisors LLC purchased a new stake in DexCom during the 4th quarter worth $26,000. Private Ocean LLC acquired a new position in DexCom in the 1st quarter worth $36,000. Canton Hathaway LLC acquired a new position in DexCom in the 1st quarter worth $41,000. Bremer Bank National Association acquired a new position in DexCom in the 1st quarter worth $42,000. Finally, Bremer Trust National Association acquired a new position in DexCom in the 4th quarter worth $49,000. 96.41% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Google Finance Portfolio Workaround

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.